Medicare Rx Formulary Design Should Prevent Risk Selection – Rep. Waxman
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS faces a dilemma in trying to satisfy both plan providers and manufacturers, Waxman acknowledges, and says that the agency should ensure that formularies do not discourage use by high-cost beneficiaries.
You may also be interested in...
Humana Sees "Very Solid" Business Opportunity in Medicare Part D
Humana's "footprint" area includes 16 mil. Medicare eligibles, many currently uncovered by a Medicare Advantage PPO. The insurer plans a stand-alone drug plan in 31 regions and a Medicare Advantage plan in 16 regions. Providing its own in-house PBM services could offer an advantage, the company suggests.
Humana Sees "Very Solid" Business Opportunity in Medicare Part D
Humana's "footprint" area includes 16 mil. Medicare eligibles, many currently uncovered by a Medicare Advantage PPO. The insurer plans a stand-alone drug plan in 31 regions and a Medicare Advantage plan in 16 regions. Providing its own in-house PBM services could offer an advantage, the company suggests.
Reimportation Is "Phony" Issue, Waxman Says, But Driven By Real Pricing Problems
Reimportation is not the solution to high U.S. drug prices, Rep. Henry Waxman (D-Calif.) said